Aardvark Therapeutics, Inc. announced progress in its Phase 3 HERO trial for ARD-101, aimed at treating hyperphagia associated with Prader-Willi Syndrome, with data expected in early 2026.

The company also reported the drug was well tolerated by study participants. In December, Aardvark began a Phase 3 study enrolling patients age 13 and older with hyperphagia that is associated ...

“The Phase 3 HERO study of ARD-101 in PWS shows our commitment to addressing unmet needs in this community.” Summary of Business Highlights In February 2025, Aardvark successfully completed ...

Aardvark’s common stock is expected to begin ... and was well-tolerated in Phase 2 trials and has entered Phase 3 development for hyperphagia associated with Prader-Willi Syndrome, for which ...

ARD-101 is entering Phase 3 trials for Prader-Willi syndrome, and leadership expects a readout of topline data in early 2026. Aardvark has booked a fair market value investment of $130.1 million ...

About Aardvark Therapeutics ... Our lead compound, oral ARD-101, is in Phase 3 clinical development for the treatment of hyperphagia associated with PWS, a rare disease characterized by insatiable ...

In other recent news, Aardvark Therapeutics Inc. has been the focus of several analyst evaluations following developments in the Prader-Willi Syndrome (PWS) treatment landscape. RBC Capital Markets ...

Aardvark, a novel machine learning-based weather ... a weather data set, followed by 3 hours of fine-tuning using the encoder's output. There are eleven decoder modules, each of which has about ...